Compare IGR & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGR | KALV |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 757.7M |
| IPO Year | N/A | 2014 |
| Metric | IGR | KALV |
|---|---|---|
| Price | $4.54 | $16.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 709.7K | ★ 747.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $4.20 | $9.83 |
| 52 Week High | $5.37 | $19.00 |
| Indicator | IGR | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 29.41 | 56.12 |
| Support Level | $4.49 | $14.59 |
| Resistance Level | $5.04 | $19.00 |
| Average True Range (ATR) | 0.08 | 0.92 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 0.99 | 49.20 |
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.